First, serum levels of LGALS3BP and CA125 (Cancer Antigen 125) were found to be elevated in 73 ovarian cancer patients and 70 patients with benign gynecological conditions, respectively, and the sensitivity increased to 86% when a combination of the two markers was used. Here, MUC16 is linked to ovarian cancer.